{"brief_title": "Phase II Trial of Allovectin-7\u00ae for Metastatic Melanoma", "brief_summary": "The purpose of this clinical trial is to determine if Allovectin-7\u00ae, an experimental gene-based immunotherapy, can shrink melanoma tumors. The trial will also examine if this treatment can improve the time to disease progression.", "detailed_description": "Treatment - If you take part in this trial you will be treated for about 10 weeks. You will receive an injection of Allovectin-7\u00ae by needle, directly into one or more selected tumors once a week for the first six weeks. The injections may be given in a doctor's office. During a four-week observation period, your disease will be measured to see if the treatment is working. This will be done by general physical exams and scans (such as X-ray scans). Patients who show no sign of disease progression may be offered an option to repeat this treatment course.", "condition": ["Melanoma", "Metastatic Melanoma", "Malignant Melanoma", "Skin Cancer"], "intervention_type": ["Genetic"], "intervention_name": ["Allovectin-7\u00ae"], "criteria": "In order to be in this trial, you must meet the enrollment criteria. Below is a list of some of the enrollment criteria. - You have been diagnosed with Stage III or Stage IV melanoma - Your cancer has returned after a prior treatment (e.g. radiation or chemotherapy) or you refused therapy with standard treatment - You are able to carry out your normal daily activities - Your melanoma has not spread to your brain", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Allovectin-7\u00ae", "mesh_term": ["Melanoma", "Skin Neoplasms"], "id": "NCT00044356"}